July 20, 2020
1 min read
Save
Allergan to withdraw abicipar pegol applications in Europe, Japan
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Allergan intends to withdraw application filings for abicipar pegol in Europe and Japan, according to a press release from Molecular Partners.
Molecular Partners is developing the DARPin therapeutic for treatment of neovascular age-related macular degeneration.
The decision to withdraw applications to the European Medicines Agency and the Japanese Regulatory Agency follow the FDA decision to deny approval of abicipar pegol for wet AMD in the U.S. due to the rate of intraocular inflammation observed.
AbbVie, Allergan’s parent company, will continue working with the agencies regarding potential resubmissions, the release said.
Published by:
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.